Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 2,103 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Hidradenitis Suppurativa
Interventions: MEDI8968, Saline; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 27
States / cities: Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more

Conditions: Thyroid Eye Disease
Interventions: Teprotumumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Beverly Hills, California • Los Angeles, California • Miami, Florida + 5 more

Conditions: Muscle Atrophy, ACL Reconstruction, Trauma, Osteoarthritis
Interventions: Testosterone, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Graft vs. Host Disease
Interventions: Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Stroke, Rehabilitation, Hand
Interventions: transcranial direct current stimulation and electrical stimulator; Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cardiovascular Risk Factor
Interventions: No to Low Endogenous Estrogen, Estradiol; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Osteoarthritis, Knee
Interventions: Hyaluronic Acid, Amniotic Tissue Allograft, Saline; Device · Drug
Lead sponsor: The Stone Research Foundation for Sports Medicine and Arthritis; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Interventions: Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection; Biological · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington

Conditions: Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Saline Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Jamaica Plain, Massachusetts

Conditions: Squamous Cell Carcinoma of the Oral Cavity
Interventions: GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo; Drug
Lead sponsor: Gliknik Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Intracerebral Hemorrhage
Interventions: Intravenous nicardipine hydrochloride; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
Interventions: Bacillus Calmette-Guérin, Saline Injection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Tissue Expansion, Breast Reconstruction
Interventions: Tissue Expansion; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Knee
Interventions: Pentosan Polysulfate Sodium twice weekly, Placebo; Drug
Lead sponsor: Paradigm Biopharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 41
States / cities: Peoria, Arizona • Tucson, Arizona • Anaheim, California + 34 more

Conditions: Pain
Interventions: Botulinum Toxin Type A, Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Nasal Fracture, Deviated Nasal Septum
Interventions: Nerve block, Placebo Saline Injection; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumours
Interventions: SB-715992, carboplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: FXI
Interventions: FXI-GalNAc-siRNA, Placebo; Drug · Other
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Creve Coeur, Missouri

Conditions: Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
Interventions: TTAX03, Saline; Biological
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more

Conditions: Pain
Interventions: Intravenous acetominophen, Ketorolac, intramuscular, Bupivacaine, subcutaneous, Normal saline; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Galveston, Texas

Search by objective public record fields.

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Testosterone Administration and ACL Reconstruction in Men

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

Improving Stroke Motor Control With Non-invasive Brain Stimulation and Functional Electrical Stimulation

Menopause Effects on Vascular Function

Stem Cell and Growth Factor Injury and Arthritis Clinical Research Study

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Study of Tirzepatide for Recovery and Alcohol Use Management

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Patient Performed Tissue Expansion for Two-stage Alloplastic Breast Reconstruction

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

Preoperative Nerve Block for Rhinoplasty/Septoplasty

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

Multimodal Pain Management for Cesarean Delivery